Fujita J, Saijo N, Eguchi K, Shinkai T, Tominaga K, Sasaki Y, Futami H, Sakurai M, Ishihara J, Takahashi H
Jpn J Cancer Res. 1985 Sep;76(9):902-5.
A phase II study of vindesine (VDS) was carried out in 21 patients with non-small cell lung cancer (NSCLC). There were 13 and 8 patients with and without prior chemotherapy, respectively. VDS was administered at a weekly iv dose of 3 mg/m2. Partial response was observed in two of 15 adenocarcinomas and one of 2 adenosquamous cell carcinomas, and the overall response rate was 14.3% (3/21). Myelosuppression, especially leukopenia, was the most common dose-limiting side effect. Neurotoxicity was also a common side effect but the degree was mild. It was concluded that VDS at a dose of 3 mg/m2 every week seems to be active against NSCLC.
对21例非小细胞肺癌（NSCLC）患者进行了长春地辛（VDS）的II期研究。其中分别有13例和8例患者接受过和未接受过化疗。VDS静脉注射剂量为每周3mg/m²。15例腺癌患者中有2例、2例腺鳞癌患者中有1例出现部分缓解，总缓解率为14.3%（3/21）。骨髓抑制，尤其是白细胞减少，是最常见的剂量限制性副作用。神经毒性也是常见副作用，但程度较轻。得出的结论是，每周剂量为3mg/m²的VDS似乎对NSCLC有活性。
